[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-solid-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-solid-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,76,121,145,167,198,235,256,277,298,324,345,366,388,409],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100609379","phase-1-a-study-to-assess-the-safety-tolerability-pharmacokinetic-pharmacodynamic-immunogenicity-and-antitumour-activity-of-ipn60300-in-adults-with-locally-advanced-or-metastatic-solid-tumours-100609379",false,"NCT07213817","A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","An Open-Label, Phase I\u002FII First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.","Inclusion criteria:\n\n* Participant must be ≥18 years of age, at the time of signing the informed consent.\n* Participants with histologically or cytologically documented, locally advanced, or metastatic solid tumors, that relapsed or were refractory after being previously treated with standard of care therapy; or for which there is no available established therapy; or standard therapy is contraindicated or not deemed appropriate by the treating investigator.\n* Participants must have measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Male and female participants Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Adequate bone marrow function within 7 days before first dose of study intervention,\n* Adequate renal function within 7 days before first dose of study intervention,\n* Adequate hepatic function or laboratory abnormalities indicating hepatic injury within 7 days before first dose of study intervention,\n* Prothrombin time or international normalised ratio (INR) ≤1.5 × ULN.\n* At the time of screening, a tumour tissue specimen is required for enrolment into the dose escalation and dose optimisation portions of the study for retrospective central laboratory determination.\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n* Have a life expectancy of more than 3 months for disease-related mortality, as evaluated by the investigator.\n\nExclusion Criteria:\n\n* Known second malignancy either progressing or requiring active treatment within the last 2 years prior to first dose of study intervention.\n* Residual toxicity from prior anticancer therapy that are NCI CTCAE version 5.0 Grade 2 or higher. Stable chronic Grade 2 toxicities from previous treatments may be eligible per the judgement of investigator.\n* History of major surgery within 4 weeks prior to the first dose of study intervention.\n* Previous solid organ transplantation.\n* Pre-existing, acute or chronic severe corneal disorders, sequelae from severe corneal disorders, or a history of corneal transplantation.\n* Active brain metastases or leptomeningeal metastases with exception to asymptomatic and treated brain metastases (i.e. no neurological symptoms, no requirements for corticosteroids and lesions \\\u003C1.5 cm), which are stable and not expected to become symptomatic in the next 3 months in the opinion of the investigator.\n* History of stroke or significant cerebrovascular disease (ie, transient ischemic attack) within 6 months prior to initiation of study intervention.\n* History of clinically significant cardiac disease within 6 months prior to the initiation of study intervention, including but not limited to unstable angina, acute myocardial infarction, endoscopic or open-heart cardiac surgery, or heart failure classified as New York Heart Association Grade 2 or higher.\n* History of clinically significant respiratory disease within 6 months prior to the initiation of study intervention, including severe chronic obstructive pulmonary disease or asthma.\n* History of noninfectious interstitial lung disease (ILD)\u002Fpneumonitis\u002Fradiation pneumonitis that required steroids or has current ILD\u002Fpneumonitis.\n* Clinically significant gastrointestinal disorder including bleeding, occlusion, diarrhoea \\>Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.\n* Any evidence of severe active infection or inflammatory condition.\n* Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.\n* Participants with uncontrolled human immunodeficiency virus (HIV). HIV infected participants are eligible if they meet criteria described in the protocol.\n* Known active infection with hepatitis B virus (HBV) OR hepatitis C virus (HCV). Participants are eligible if they meet criteria described in the protocol.\n* Ongoing immunosuppressive therapy, including systemic corticosteroids. NOTE: Physiologic replacement or use of topical or inhaled corticosteroids are allowed.\n* Concurrent participation in another therapeutic treatment trial, previous participation should respect the minimum of 5 half-lives or 4 weeks before the study intervention initiation (whichever is shorter).\n* Participants accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.\n* For French participants only: participants are under court protection, not affiliated to a social security system or protected adults.","ALL","18 Years",{"count":19,"type":20},114,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection.\n\nStudy Phases:\n\n* Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose).\n* Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance).\n\nStudy Periods:\n\nScreening: Up to 28 days before first IPN60300 injection to determine eligibility.\n\nTreatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor.\n\nParticipants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.",[27,28],"Locally Advanced Solid Tumor","Metastatic Solid Tumor","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2025-12-05",{"date":37,"type":20},"2028-10-30",{"name":39,"class":40},"Ipsen","INDUSTRY",12,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100591052","phase-1-clinical-trial-of-yh32364-in-patients-with-locally-advanced-or-metastatic-egfr-overexpressing-solid-tumors-100591052","NCT06975410","Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","A Phase 1\u002F2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Must sign an informed consent form (ICF) prior to any study specific procedures\n* ECOG performance status 0 or 1\n* Estimated life expectancy of at least 3 months\n* A woman must not be breastfeeding\n* Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.\n\n\\[Dose Escalation Only\\] Locally advanced or metastatic EGFR overexpressing solid tumor\\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy\n\n\\* One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.\n\n* Head and neck squamous cell carcinoma (HNSCC)\n* Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)\n* Esophageal squamous cell carcinoma (ESCC)\n* Biliary tract cancer (BTC)\n* Uterine cervical cancer\n* Vulvar cancer\n* Urothelial cancer\n* Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)\n\n\\[Dose Expansion Only\\] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)\\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.\n\nExclusion Criteria:\n\n* Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and\u002For carcinomatous meningitis\n* Have history of a second primary cancer with the exception of\n\n  * curatively treated non-melanomatous skin cancer\n  * curatively treated cervical or breast carcinoma in situ, or\n  * other malignancy with no known active disease present and no treatment administered during the last 2 years\n* Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)\n* Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks\n* Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis\n* Have autoimmune disease that has required systemic treatment\n* Infection with human immunodeficiency virus (HIV)\n* Active chronic hepatitis B or chronic hepatitis C\n\n\\[Prior\u002FConcomitant Therapy\\]\n\n* Have received systemic steroid therapy\n* Previous treatment with a 4-1BB\u002FCD137-modulating agent\n* Have used a live vaccine within 4 weeks\n* Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies\n* Have received radiation therapy\n* Have received cytotoxic chemotherapy",{"count":50,"type":20},80,[23,24],"This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.",[54,27,28],"EGFR Overexpression",[56,57,58,59,60,61,62,63,64,65],"YH32364","EGFR\u002F4-1BB bispecific antibody","Solid tumor","Head and neck squamous cell carcinoma (HNSCC)","Non-small cell lung cancer (NSCLC)","Esophageal squamous cell carcinoma (ESCC)","Biliary tract cancer (BTC)","Uterine cervical cancer","Vulvar cancer","Urothelial cancer","2026-06-09",{"date":68,"type":33},"2026-06-10",{"date":70,"type":33},"2025-06-12",{"date":72,"type":20},"2029-12",{"name":74,"class":40},"Yuhan Corporation",4,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":102,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100509886","phase-1-fog-001-in-locally-advanced-or-metastatic-solid-tumors-100509886","NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors","A Phase 1\u002F2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):\n\n* Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):\n\n* Desmoid tumor (aggressive fibromatosis)\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n* One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab\n\n* Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.\n* MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1\u002FPD-L1\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine\u002FTipiracil + Bevacizumab\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2a):\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2b):\n\n* Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence\n\nExclusion Criteria:\n\n* Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.\n* Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)\n* Unstable\u002Finadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.",{"count":84,"type":20},595,[23,24],"The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.",[88,89,90,27,91,92,93,94,95,96,97,98,99,100,101],"Cancer","Colorectal Cancer","Solid Tumor","Metastatic Cancer","WNT Pathway","HCC","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","FAP","Endometrial Carcinoma","Prostate Cancer","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma",[88,90,27,91,103,104,105,94,106,107,108,109,110],"WNT Pathway Activating Mutation (WPAM)","Colorectal Cancer (CRC)","Microsatellite Stable (MSS)","Hepatocellular Carcinoma (HCC)","Adenomatous Polyposis Coli (APC)","β-catenin","Beta-catenin","CTNNB1","2026-05-26",{"date":113,"type":33},"2026-05-28",{"date":115,"type":33},"2023-05-23",{"date":117,"type":20},"2027-08-31",{"name":119,"class":40},"Parabilis Medicines, Inc.",33,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100624030","phase-1-5-azacitidine-plus-pd-1pd-l1-inhibitor-with-pd-1pd-l1-refractory-tumors-100624030","NCT07404332","5-Azacitidine Plus PD-1\u002FPD-L1 Inhibitor With PD-1\u002FPD-L1 Refractory Tumors","Phase I Study of 5-Azacitidine Plus PD-1\u002FPD-L1 Inhibitor in Patients With PD-1\u002FPD-L1 Refractory Tumors","Inclusion Criteria:\n\n* Written and voluntary informed consent.\n* At least 18 years of age or older.\n* Histologically and radiologically confirmed locally advanced or metastatic unresectable solid tumor malignancy for which PD-1 or PD-L1 therapy is already approved by the FDA. Locally advanced is defined as unresectable in the opinion of the treating physician. A repeat biopsy is required if previous biopsy tissue is unavailable.\n* At least one Response Evaluation Criteria in Solid Tumors (RECIST 1.1) - defined target lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry on all pre-disease performance without restriction), 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work), or 2 (ambulatory and capable of self-care but unable to carry out any work activities, spending more than 50% of waking hours up and about).\n* Documented progression on PD1 or PD-L1 inhibitors.\n* Recovery from any acute toxicity associated with prior therapy to grade 1.\n* Renal function (creatinine level within normal institutional limit, or creatinine clearance \\>15 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, calculated using the Cockcroft-Gault formula).\n* Liver function (AST\u002FALT \\\u003C3.0 X institutional upper limit of normal OR \\\u003C5 X institutional upper limit of normal in cases of liver metastasis; total bilirubin ≤ 1.5 times upper limit of normal).\n* Adequate hematological lab values including:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1.0 X 109\u002FL\n  * Platelets ≥ 100X109\u002FL\n  * Hemoglobin ≥ 7.0 g\u002FdL\n* Female subjects of childbearing potential and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of contraception from time of screening, throughout the whole duration of the drug treatment, and during the 6-month post-treatment washout period.\n* Patients may have previously received a hypomethylating agent, as long as it was not given in combination with ipilimumab.\n* Patients may have previously received ipilimumab but must have relapsed or progressed while on therapy.\n* Patients must have adequate archival tissue available for the purpose of downstream methylation status assessment, immunohistochemistry, RNA expression (10 slides at 5µM). If archival tissue is not available, a repeat biopsy is required.\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with active, untreated metastases in the central nervous system.\n* Patients who are pregnant or breastfeeding.\n* Patients who have an active infection.\n* Patients with significant hematologic, hepatic, and renal function impairment.\n* Patients who are being treated for any concurrent medical condition requiring the use of systemic steroids or history of long-term use of systemic steroids.\n* Patients who have a history of inflammatory bowel disease or a history of symptomatic autoimmune disease.\n* Patients who have had any major surgical procedure or significant traumatic injury within 28 days prior to study enrollment.\n* Patients who have received chemotherapy, immunosuppressive agents or any investigational drug within 28 days prior to starting the study drugs.\n* Patients who have any underlying medical condition which, in the treating physician's opinion, will make the administration of study drugs hazardous or obscure the interpretation of adverse events.","99 Years",{"count":130,"type":20},35,[23],"This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1\u002FPD-L1 inhibitors in patients with tumors refractory to PD-1\u002FPD-L1 inhibitors, for which such treatments have been approved.",[90,27,134],"Metastatic Tumor","2026-05-22",{"date":113,"type":33},{"date":138,"type":33},"2026-02-11",{"date":140,"type":20},"2031-02-28",{"name":142,"class":143},"Mohammed Milhem","OTHER",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100468810","phase-1-a-study-of-neladalkib-nvl-655-in-patients-with-advanced-nsclc-and-other-solid-tumors-harboring-alk-rearrangement-or-activating-alk-mutation-alkove-1-100468810","NCT05384626","A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","A Phase 1\u002F2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)","Inclusion Criteria:\n\n1. Age ≥18 years, Phase 2 Cohort 2f only: Age ≥12 years and weighing \\>40 kg. DDI sub-study Cohorts G and H only: age 18-60 years, inclusive\n2. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.\n3. Phase 2\n\n   1. Phase 2 Cohorts except 2f: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement\n   2. Phase 2 Cohort 2f: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation detected by certified assay.\n4. DDI sub-study cohorts: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement\n5. DDI sub-study cohorts: Must have previously received ≥1 ALK TKI; no prior investigational agents targeting ALK; any number of prior chemotherapy and\u002For immunotherapy\n6. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1\n7. Adequate organ function and bone marrow reserve\n\nExclusion criteria:\n\n1. Patient's cancer has a known oncogenic driver alteration other than ALK.\n2. Known allergy\u002Fhypersensitivity to excipients of NVL-655.\n3. Major surgery within 4 weeks of the study entry\n4. Ongoing or anticancer therapy\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.","12 Years",{"count":154,"type":20},840,[23,24],"Phase 1\u002F2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.\n\nPhase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors.\n\nPhase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors.\n\nA drug-drug interaction (DDI) sub-study will determine the effect of neladalkib on the pharmacokinetics of midazolam and repaglinide, as well as the effect of itraconazole on the pharmacokinetics of neladalkib, in patients with advanced ALK-positive NSCLC",[27,28],{"date":159,"type":33},"2026-05-27",{"date":161,"type":33},"2022-06-09",{"date":163,"type":20},"2028-01",{"name":165,"class":40},"Nuvalent Inc.",74,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":144},"100548055","phase-2-lattice-radiotherapy-for-dose-escalated-palliation-of-bulky-tumors-100548055","NCT06416007","Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","Inclusion Criteria:\n\n* Solid tumor malignancy with a clinical indication for radiation\n* Patients must have measurable disease\n* Target lesion(s) which are amenable to lattice therapy plan\n* When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy\n* Age ≥18 years.\n* ECOG Performance status ≤2\n* Life expectancy greater than 3 months\n* Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.\n* Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.\n* Patients with a history of conditions which predispose them to increased radiation toxicity\n* Patients with known contraindications to radiation therapy\n* Patients with uncontrolled intercurrent illness\n* Pregnant women",{"count":175,"type":20},37,[24],"The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.",[88,91,179,27,180],"Locally Advanced","Locally Advanced Carcinoma",[182,183,184,185,186,187,188],"Radiation","Radiotherapy","Bulky","Spatial fractionation","Lattice therapy","Palliative","Palliation","2026-04-28",{"date":191,"type":33},"2026-05-04",{"date":193,"type":33},"2024-08-02",{"date":195,"type":20},"2027-06-01",{"name":197,"class":143},"University of Cincinnati",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100495563","phase-1-safety-and-tolerability-of-tng462-in-patients-with-mtap-deleted-solid-tumors-100495563","NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","A Phase 1\u002F2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Age: ≥18 years-of-age at the time of signature of the main study ICF\n2. Performance status: ECOG Performance Score of 0 to 1\n3. Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and\u002For unresectable solid tumor\n4. Prior standard therapy, as available\n5. Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC.\n6. Adequate organ function\u002Freserve per local labs\n7. Adequate liver function per local labs\n8. Adequate renal function per local labs\n9. Negative serum pregnancy test result at screening\n10. Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n1. Known allergies, hypersensitivity, or intolerance to TNG462, or its excipients or to pembrolizumab in the combination treatment arms\n2. Uncontrolled intercurrent illness that will limit compliance with the study requirements\n3. Active infection requiring systemic therapy\n4. Currently participating in or has planned participation in a study of another investigational agent or device\n5. Impairment of GI function or disease that may significantly alter the absorption of oral TNG462\n6. Active prior or concurrent malignancy.\n7. Central nervous system metastases associated with progressive neurological symptoms\n8. Current active liver disease from any cause\n9. Known to be HIV positive, unless all of the following criteria are met:\n\n   1. CD4+ count ≥300\u002FμL\n   2. Undetectable viral load\n   3. Receiving highly active antiretroviral therapy\n10. Clinically relevant cardiovascular disease\n11. A female patient who is pregnant or lactating\n12. Patient is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, biopsy, or other study procedures and study restrictions\n13. Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the safety of the patient or impair the assessment of study results",{"count":206,"type":20},225,[23,24],"This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.",[27],[211,212,213,214,215,216,217,218,219,220,221,222,223,224],"MTAP deletion","PRMT5","cholangiocarcinoma","NSCLC","mesothelioma","MPNST","Tango","pancreatic","sarcoma","urothelial","gallbladder","liver","renal","breast","2026-04-17",{"date":227,"type":33},"2026-04-21",{"date":229,"type":33},"2023-05-26",{"date":231,"type":20},"2026-09",{"name":233,"class":40},"Tango Therapeutics, Inc.",26,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},"100556166","phase-1-a-study-of-nvl-330-in-patients-with-advanced-or-metastatic-her2-altered-nsclc-heroex-1-100556166","NCT06521554","A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","A Phase 1a\u002F1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC\n3. Documented HER2 status as follows:\n\n   1. Phase 1a: Documented oncogenic HER2 mutation such as HER2 exon20 insertion mutations or single nucleotide variants or HER2 amplification.\n   2. Phase 1b: Documented oncogenic HER2 mutation.\n4. Identification of lesions as follows:\n\n   1. Phase 1a: Must have evaluable disease (target or nontarget) according to RECIST 1.1.\n   2. Phase 1b: Must have measurable disease, defined as ≥ 1 radiologically measurable target lesion according to RECIST 1.1.\n5. Adequate organ function and bone marrow reserve\n\nExclusion Criteria:\n\n1. Participant's cancer has known oncogenic driver alteration other than HER2\n2. Known allergy\u002Fhypersensitivity to excipients of NVL-330\n3. Major surgery within 4 weeks of the first dose of study drug\n4. Ongoing or recent anticancer therapy\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study",{"count":243,"type":20},200,[23],"Phase 1a\u002F1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-small lung cancer (NSCLC).\n\nPhase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD.\n\nPhase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in participants with advanced or metastatic HER2 mutant NSCLC.",[27,28],"2026-02-23",{"date":249,"type":33},"2026-02-25",{"date":251,"type":33},"2024-07-18",{"date":253,"type":20},"2027-02",{"name":165,"class":40},21,{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":144},"100543654","phase-2-topical-tretinoin-prophylaxis-for-anti-egfr-induced-skin-toxicity-in-patients-with-solid-tumors-100543654","NCT06358677","Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors","A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors","FACE","Inclusion Criteria:\n\n* Participant aged ≥ 18 years\n* Histologically confirmed solid tumor.\n* Radiologically confirmed locally advanced or metastatic disease.\n* Eligible for and willing to receive treatment with panitumumab or cetuximab as standard-of-care.\n* ECOG Performance Status ≤ 2.\n* Adequate organ function as defined as:\n\n  --Hepatic:\n  * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN ----Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n* Negative pregnancy test for participants who have not undergone surgical sterilization or shown evidence of post-menopausal status. The following age-specific requirements apply:\n\n  --\\\u003C 50 years of age:\n  * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n  * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n  * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n\n    --≥ 50 years of age:\n  * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n  * Had radiation-induced menopause with last menses \\>1 year ago; or\n  * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n  * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.2.\n* Must have recovered from adverse effects of any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy). CTCAE adverse events less than or equal to grade 1 are acceptable. CTCAE adverse events grade 2 or greater may be acceptable as determined by an investigator with appropriate documentation.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Treatment with an anti-EGFR agent within 90 days of registration.\n* Pre-existing facial rash that per the treating investigator would preclude the ability to assess response to topical tretinoin.\n* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and\u002For will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).\n* Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* Systemic active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).\n* Participants taking prohibited medications as described in Section 6.8.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",{"count":265,"type":20},25,[24],"The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment.\n\nResearchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.",[28,27],{"date":270,"type":33},"2026-02-13",{"date":272,"type":33},"2025-02-19",{"date":274,"type":20},"2029-07",{"name":276,"class":143},"University of Utah",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":75},"100557136","phase-2-cd8-pet-imaging-in-metastatic-solid-tumours-100557136","NCT06534190","CD8 PET Imaging in Metastatic Solid Tumours","A Phase II, Open Label, Multi-center Study of 89Zr-DF-Crefmirlimab for CD8 Positron Emission Tomography in Patients With Locally Advanced or Metastatic Solid Tumours","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of signing informed consent.\n2. Patients with histologically confirmed diagnosis of locally advanced or metastatic solid cancer types who, according to the opinion of the principal investigator, based on available clinical data, may benefit from anti-PD1 antibody therapy.\n3. Disease progression following first-line therapy or any subsequent treatment line or no superior standard line of therapy available.\n4. At least 1 lesion that is accessible per investigator's assessment and eligible for biopsy according to standard clinical care procedures.\n5. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions except for lesions that have progressed after radiotherapy administered at least 3 months earlier.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Life expectancy ≥ 12 weeks.\n8. Adequate organ and bone marrow function as defined below:\n\n   1. Hemoglobin ≥9.0 g\u002FdL\n   2. Absolute neutrophil count ≥1.0 x 109\u002FL\n   3. Absolute lymphocyte count ≥0.75 x 109\u002FL\n   4. Platelet count ≥75 x 109\u002FL\n   5. Serum creatinine ≤1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate \\> 30 mL\u002Fmin\u002F1.73 m2. A 24-hour urine creatinine collection may substitute for the calculated creatinine clearance to meet eligibility criteria.\n   6. Adequate hepatic function:\n\n   i. Total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumour involvement); Patients with Gilbert's syndrome do not need to meet total bilirubin requirements, provided their total bilirubin is unchanged from their baseline. Gilbert's syndrome must be documented appropriately as past medical history.\n\n   ii. Aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x ULN if liver tumour involvement) iii. Alanine aminotransferase (ALT) ≤2.5 x ULN (≤5 x ULN if liver tumour involvement) iv. Alkaline phosphatase (ALP) ≤2.5 x ULN (≤5 x ULN if liver or bone tumour involvement)\n9. Signed informed consent.\n10. Willingness and ability to comply with all protocol required procedures.\n11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate (\\\u003C 1% per year) when used consistently and correctly)).\n\nExclusion Criteria:\n\n1. Treatment with any approved anti-cancer therapy, investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to 89Zr-Df-crefmirlimab infusion and nivolumab or cetrelimab treatment.\n2. Symptomatic, untreated brain metastasis, leptomeningeal disease, or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated and neurologically stable for at least 2 weeks prior to enrollment.\n3. Prior ICI treatment, including but not limited to anti-PD1, anti-PD-L1 and anti-CTLA4 therapeutic antibodies.\n4. Major surgical procedure other than for diagnosis within 28 days prior to 89Zr-Df-crefmirlimab infusion or anticipation of need for a major surgical procedure during the course of the study.\n5. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematous, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.\n\n   * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for his study.\n   * Patients with controlled type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.\n6. Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumour necrosis factor agents) within 4 weeks prior to 89Zr-Df-crefmirlimab infusion.\n\n   * Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the sponsor.\n   * The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.\n7. Prior allogeneic bone marrow transplantation or solid organ transplant.\n8. Active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or tuberculosis infection; or diagnosis of immunodeficiency.\n\n   * Patients will be tested for hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening.\n   * Patients with known HIV infection who have controlled infection (undetectable viral load (HIV ribonucleic acid (RNA) polymerase chain reaction (PCR)) and CD4 count above 350 either spontaneously or on a stable antiviral regimen are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards.\n   * Patients with hepatitis B who have a controlled infection (serum HBV deoxyribonucleic acid (DNA) PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug.\n   * Patients who are HCV antibody positive who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.\n   * Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.\n9. Receipt of a live vaccine (including attenuated) within 30 days of planned start of study medication.\n10. Evidence of an active infection that requires systemic antibiotics within 2 weeks prior to 89Zr-Df-crefmirlimab infusion.\n11. At least 2 weeks recovered from COVID 19 infection, where this infection has to be documented in the case record form.\n12. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of 89Zr-Df-crefmirlimab, or that may affect the interpretation of the results or render the patient at high risk from complications.\n13. Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n14. Sponsor employee\u002Fmember of the clinical site study team and\u002For his or her immediate family\n15. Women with a positive serum chorionic gonadotropin HCG pregnancy test at the screening\u002Fbaseline visit. Breastfeeding women are also excluded.\n16. Women of childbearing potential\\* and sexually active men who are unwilling to practice highly effective contraception prior to the first dose of study therapy, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include:\n\n    * stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening\n    * intrauterine device (IUD); intrauterine hormone-releasing system (IUS)\n    * bilateral tubal ligation\n    * vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the women of childbearing potential (WOCBP) study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure)\n    * and\u002For sexual abstinence.\n17. Contraindications for MRI scan\n18. Patients who have any splenic disorders, or had splenectomy, that could compromise protocol objectives",{"count":285,"type":20},30,[24],"This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.",[27],"2026-02-05",{"date":291,"type":33},"2026-02-09",{"date":293,"type":33},"2025-03-11",{"date":295,"type":20},"2028-11",{"name":297,"class":143},"University Medical Center Groningen",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100530227","phase-1-a-dose-escalation-and-expansion-study-of-177lulu-sn201-in-participants-with-advanced-cancer-100530227","NCT06184035","A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","Ph I\u002FIIa Escalation\u002FExpansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive\u002FTreatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors","Tumorad","Inclusion criteria:\n\n1. Male or female participants ≥ 18 years of age on the day of signing informed consent.\n2. Histologically or cytologically documented, recurrent, locally advanced, or metastatic solid malignancy that has failed at least one prior systemic standard therapy, or for which standard therapy is not appropriate, or for which no standard therapy exists.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n4. Life expectancy ≥ 3 months.\n5. Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 28 days before the start of the study IMP administration:\n\n   1. Hemoglobin ≥ 9.0 g\u002FdL (transfusions are allowed).\n   2. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3.\n   3. Platelet count ≥ 100,000 mm3.\n   4. Total bilirubin ≤ 2.5 x upper limit of normal (ULN) (in participants with liver metastases ≤ 5 ULN).\n   5. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 x ULN.\n6. On a stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and prothrombin\u002Finternational normalized ratio and partial thromboplastin time (PT\u002FINR and PTT, respectively) test results are compatible with the acceptable benefit-risk ratio at the Investigator's discretion.\n7. Serum creatinine ≤ 1.5 x ULN and estimated glomerular filtration rate (eGFR) \\> 30 mL\u002Fmin\u002F1.73 m2 (per local values).\n8. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n   1. Male participants must agree to use a highly effective method of birth control as defined in ICH M3(R2) starting with the first dose of study medication through 120 days after the last dose of study medication.\n   2. Female participants of childbearing potential\\* must have a negative pregnancy test documented at Screening and Baseline and be willing to use a highly effective method of contraception\\*\\* or practice abstinence starting from ICF signature through to 120 days after the last dose of study medication.\n\n      * A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., had had menses at any time in the preceding 24 consecutive months).\n\n        * Effective contraception is defined as contraceptive methods with a failure rate of \\\u003C 1% to prevent pregnancy (combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, implantable\\], intrauterine device \\[IUD\\] or intrauterine hormone-releasing system).\n9. Written informed consent to study participation.\n10. Be able to understand and comply with the requirements of the study, as judged by the Investigator.\n11. Phase I: At least one lesion as per RECIST v1.1.\n12. Phase IIa: At least one measurable lesion as per RECIST v1.1.\n\nExclusion criteria:\n\n1. Unstable systemic disease (including but not limited to active infection, hepatic, renal, or metabolic disease).\n2. Clinically significant cardiac disease including any of the following:\n\n   1. Congestive heart failure requiring treatment (New York Heart Association Grade ≥ 2).\n   2. LVEF of \\\u003C 50%, as determined by MUGA or ECHO.\n   3. Uncontrolled hypertension, defined as persistent systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite current therapy.\n   4. History or presence of clinically significant ventricular arrhythmias or atrial fibrillation.\n   5. Clinically significant resting bradycardia.\n   6. Unstable angina pectoris ≤ 3 months before the start of study treatment.\n   7. Acute myocardial infarction ≤ 3 months before the start of study treatment.\n   8. Mean triplicate QT interval corrected for heart rate using Fridericia's formula (QTcF) value \\> 480 msec (as specified in Section 10.5).\n3. Known hypersensitivity to pegylated drugs or vaccines (e.g., covid-19 vaccines).\n4. Concurrent or active solid or hematologic malignancy within the last 2 years with a distinct primary site or histology from the cancer being evaluated in this study except for the following cancer types: cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis).\n5. Infections not responding to therapy or active clinically serious infections.\n6. Known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection requiring treatment. Participants with chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.\n\n   NB: Participants with CNS metastases may be included after discussion with Sponsor, except for the sentinel participants.\n7. Chemotherapy, experimental cancer therapy, biologic therapy, or immunotherapy within 2 weeks (or 5 half-lives, whatever is shortest) before the start of the study IMP administration.\n8. Palliative radiotherapy completed less than 2 weeks before the start of the study IMP administration will be allowed as long as no more than 10% of the participant's bone marrow was irradiated.\n9. Not recovered to Grade 1 from any prior anti-cancer therapy, excluding alopecia.\n10. Previous high-dose chemotherapy needing hemopoietin-stem-cell-rescue.\n11. Major surgery, open biopsy, or significant trauma within 4 weeks before the start of study treatment.\n12. A psychiatric or functional disorder that prevents participants from providing informed consent or following protocol instructions.\n13. A participant that has a condition or is in a situation, in the Investigator's opinion may put the individual at significant risk, may confound the study results, or may interfere significantly with their participation in the study.\n14. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks or 5 half-lives of the agent, whichever is the shortest.",{"count":307,"type":20},90,[23,24],"The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of \\[177Lu\\]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care treatment options.\n\n\\[177Lu\\]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.",[90,91,311,312,27,313],"Unresectable Solid Tumor","Recurrent Solid Tumor","Refractory Cancer","2025-11-17",{"date":316,"type":33},"2025-11-20",{"date":318,"type":33},"2023-12-06",{"date":320,"type":20},"2027-12-31",{"name":322,"class":40},"Spago Nanomedical AB",2,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":344},"100448387","phase-1-a-study-of-zidesamtinib-nvl-520-in-patients-with-advanced-nsclc-and-other-solid-tumors-harboring-ros1-rearrangement-arros-1-100448387","NCT05118789","A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","A Phase 1\u002F2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)","Inclusion Criteria:\n\n1. Age ≥18 years (Cohort 2e only: Age ≥12 years).\n2. Disease Criteria:\n\n   1. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with documented ROS1 rearrangement.\n   2. Phase 2: Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangement.\n   3. Phase 2: Cohort 2e: Histologically or cytologically confirmed locally advanced or metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.\n3. Prior anticancer treatment (except cohort 2a).\n4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.\n5. Adequate baseline organ function and bone marrow reserve.\n\nExclusion Criteria:\n\n1. Patient's cancer has a known oncogenic driver alteration other than ROS1.\n2. Known allergy\u002Fhypersensitivity to excipients of NVL-520.\n3. Major surgery within 4 weeks of first dose of study drug.\n4. Ongoing anticancer therapy.\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.",{"count":332,"type":20},359,[23,24],"Phase 1\u002F2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors.\n\nPhase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors.\n\nPhase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of zidesamtinib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors.",[27,28],"2025-10-22",{"date":338,"type":33},"2025-10-24",{"date":340,"type":33},"2022-01-04",{"date":342,"type":20},"2028-12-31",{"name":165,"class":40},63,{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":21,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100548015","phase-1-ace2016-in-adult-subjects-with-locally-advanced-or-metastatic-solid-tumors-expressing-epidermal-growth-factor-receptor-egfr-100548015","NCT06415487","ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)","A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)","Inclusion Criteria:\n\n* Locally advanced unresectable or metastatic solid tumors that have failed at least two lines of therapy (one of which must be targeted therapy)\n* At least one measurable lesion as defined by RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate hematologic and renal, hepatic and cardiac function\n* Oxygen saturation via pulse oximeter ≥92% at rest on room air\n\nExclusion Criteria:\n\n* Prior treatment with a genetically modified cell therapy product targeting EGFR\n* History of allogeneic transplantation\n* Subjects with active CNS metastases\n* History or presence of clinically relevant Central Nervous System (CNS) disorder (e.g. epilepsy)\n* Clinically significant active infection\n* Human Immunodeficiency Virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* History of malignancies with the exception of certain treated malignancies with no evidence of disease.\n* Primary immunodeficiency disorder\n* Pregnant or lactating female\n* Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment or comply with study requirements, including understanding and rendering of informed consent",{"count":285,"type":20},[23],"ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).\n\nThe ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).",[27,28],"2025-06-28",{"date":358,"type":33},"2025-07-01",{"date":360,"type":33},"2024-08-22",{"date":362,"type":20},"2027-03-27",{"name":364,"class":40},"Acepodia Biotech, Inc.",9,{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":144},"100566682","phase-3-phase-iii-clinical-study-of-vc004-in-patients-with-localized-advanced-metastatic-solid-tumors-100566682","NCT06658353","Phase III Clinical Study of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Inclusion Criteria:\n\n* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；\n* Male or female, age ≥12 years old;\n\nExclusion Criteria:\n\n* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);\n* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);\n* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.",{"count":374,"type":20},54,[376],"PHASE3","This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced\u002Fmetastatic solid tumors.",[27],"2025-03-18",{"date":381,"type":33},"2025-03-20",{"date":383,"type":33},"2025-03-17",{"date":385,"type":20},"2026-12-30",{"name":387,"class":40},"Jiangsu vcare pharmaceutical technology co., LTD",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":21,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":406,"locationsCount":408},"100542941","phase-1-ibi3001-in-participants-with-unresectable-locally-advanced-or-metastatic-solid-tumors-100542941","NCT06349408","IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors","A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n1. Male or female participants ≥ 18 years old;\n2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;\n3. Has an anticipated life expectancy of ≥ 12 weeks;\n4. Adequate bone marrow and organ function:\n5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.\n6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.\n\nKey Exclusion Criteria:\n\n1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;\n2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;\n3. Pyloric obstruction and\u002For persistent recurrent vomiting (≥ 3 times in 24 hours);\n4. Gastrointestinal perforation and\u002For fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;\n5. Known symptomatic central nervous system (CNS) metastases.\n6. History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;\n7. History of endotracheal or gastrointestinal stent implantation;\n8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;\n9. Esophageal or gastric varices requiring immediate intervention;\n10. Not eligible to participate in this study at the discretion of the investigator;\n11. Do not have adequate treatment washout period before study drug administration. -",{"count":396,"type":20},250,[23],"This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD\u002FRP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.",[27],"2025-01-23",{"date":402,"type":33},"2025-01-27",{"date":404,"type":33},"2025-01-10",{"date":320,"type":20},{"name":407,"class":40},"Innovent Biologics (Suzhou) Co. Ltd.",5,{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":419,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":438,"leadSponsor":440,"locationsCount":144},"100518298","a-study-on-the-prevalence-of-clinically-useful-mutations-in-solid-tumor-characterized-by-next-generation-sequencing-methods-on-liquid-biopsy-analysis-popcorn-100518298","NCT06028724","A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","A Prospective, Observational Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","POPCORN","Inclusion Criteria:\n\nPatients eligible for inclusion in this study have to meet all of the following criteria:\n\n* Patients, 18 years of age or older\n* Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n* Histologically proven diagnosis solid tumor\n* Diagnosis of advanced or locally advanced disease\n* Patients candidated to receive standard therapy in the following line:\n* first, second or third-line therapy for colon-rectal cancer in IV stage\n* first or second-line therapy for gastric cancer in IV stage\n* primary intent or first-line therapy for pancreatic cancer\n* first-line therapy for bile duct cancer\n* first or second-line therapy for hepatocarcinoma\n* first, second, third, fourth or fifth-line therapy for breast cancer in IV stage\n* chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse\n* first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV)\n* first or second-line therapy for advanced or locally advanced cervical cancer\n* therapy for locally advanced or first line therapy for metastatic vulva cancer\n* first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma)\n\nExclusion Criteria:\n\n* Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints",{"count":418,"type":20},782,"OBSERVATIONAL","The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. It is used to identify potential circulating dynamic biomarkers of treatment sensitivity or resistance in a real word multi-pathology evaluation. In this way, defining the mutational status of clinical relevance genes in real world, as a predictive biomarker to identify those patients most likely to benefit from target therapy, offers the potential to optimize access to further therapies. The aim of this study is to evaluate the real-world prevalence of clinically useful mutations in patients who are receiving therapy for advanced and locally advanced solid tumor through liquid biopsy.",[90,422,27,423,424,425,426,427,428,429,430,431,432,433],"Advanced Solid Tumor","Colon Rectal Cancer","Gastric Cancer","Pancreatic Cancer","Bile Duct Cancer","Hepatocarcinoma","Breast Cancer","Ovarian Cancer","Endometrial Cancer","Cervical Cancer","Vulva Cancer","Melanoma","2023-09-08",{"date":436,"type":33},"2023-09-13",{"date":229,"type":33},{"date":439,"type":20},"2030-05-31",{"name":441,"class":143},"Centro di Riferimento Oncologico - Aviano"]